

60th Annual Meeting
of the Society of Thrombosis
and Haemostasis Research

HAEMOSTASIS

AN INDISPENSABLE, CROSS-
SECTIONAL MEDICAL DISCIPLINE



Muenster, Germany
17–20 February 2016

Final Programme
➔ www.gth2016.org



THURSDAY, 18 FEBRUARY 2016

POSTER PRESENTATIONS

- PO1-11 **Andrographolide improves cerebral ischemia/reperfusion-induced brain injury through Nrf2/HO-1 pathway**
W.-J. Lu¹, J.-R. Sheu², K.-H. Lin³
¹Taipei Medical University Hospital, Translational Laboratory, Research Department, Taipei, Taiwan, Republic of China, ²Taipei Medical University, Graduate Institute of Medical Sciences, Taipei, Taiwan, Republic of China, ³Shin-Kong Wu Ho-Su Memorial Hospital, Central Laboratory, Taipei, Taiwan, Republic of China
- PO1-12 **Factors determining the use of oral anticoagulation therapy for stroke prevention in atrial fibrillation in routine clinical practice: Insights from the BALKAN-AF Survey**
T. Potpara^{1,2}, M. Polovina¹, U. Ekmeciu³, E. Goshev⁴, D. Loncar⁵, L. Music⁶, S. Brusich⁷, A. Anic⁸, V. Paparisto⁹, E. Trendafilova⁴, C. Arsenescu Georgescu¹⁰, G.-A. Dan¹¹, G. Lip¹², BALKAN-AF Investigators
¹Belgrade University, School of Medicine, Belgrade, Serbia, ²Clinical Centre of Serbia, Cardiology Clinic, Belgrade, Serbia, ³University Hospital Center Mother Theresa, Clinic of Internal Medicine, Tirana, Albania, ⁴National Heart Hospital, Coronary Care Unit, Sofia, Bulgaria, ⁵University Clinical Center Tuzla, Clinic of Internal Medicine, Tuzla, Bosnia and Herzegovina, ⁶University of Podgorica, University Clinical Center of Montenegro, Podgorica, Montenegro, ⁷Clinical Center Rijeka, Cardiology, Rijeka, Croatia, ⁸General Hospital Zadar, Cardiology, Zadar, Croatia, ⁹University Hospital Center Mother Theresa, Cardiology Clinic, Tirana, Albania, ¹⁰Institute for Cardiovascular Diseases 'Prof Dr George I.M. Georgescu', Lasi, Romania, ¹¹Medicine University 'Carol Davila', Colentina University Hospital, Bucharest, Romania, ¹²University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom
- PO1-13 **Antithrombotic prophylaxis in women with multiple pregnancy**
J. Khizroeva¹, N. Makatsariya¹, N. Stuleva¹
¹I.M. Sechenov First Moscow State Medical University, Obstetrics and Gynecology, Moscow, Russian Federation
- PO1-14 **Enhanced procoagulant activity of monocytic leukaemia cell lines and microparticles**
R. Hudak¹, I. Deak¹, G. Szabo Gal¹, I. Beke Debreceni¹, P. Antal-Szalmas¹, J. Kappelmayer¹
¹University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary
- PO1-15 **Heparins and fucoidans inhibit the CXCR4/7 signalling axis in lymphoma cells by interaction with the chemokine CXCL12**
S. Alban¹, I. Liewert¹, T. Schneider¹, K. Ehrig¹
¹Christian-Albrechts University of Kiel, Pharmaceutical Institute, Kiel, Germany

THURSDAY, 18 FEBRUARY 2016

POSTER PRESENTATIONS

- PO1-16 **Characterization of microparticles derived from tumour cell lines**
C. Plattfaut¹, T. Quecke¹, M. Schwenke¹, F. Gieseler¹
¹University of Luebeck, Experimental Oncology, Luebeck, Germany
- PO1-17 **Sepsis-related life-threatening venous thrombosis in a newborn child successfully treated with rtPA and low molecular weight heparin – a case report**
M. Rohde¹, M. Pingel², V. Vaillant¹, H. Ehrhardt³, D. Faas³, G. Kerst⁴, J. Thul⁴, C. Mauz-Körholz¹, D. Körholz¹, B. Kemkes-Matthes⁵, H. Hauch¹
¹UKGM Hemostasis Center, Department of Pediatric Hematology and Oncology, Giessen, Germany, ²DRK Children's Hospital, Siegen, Germany, ³UKGM Department of General Pediatrics and Neonatology, Giessen, Germany, ⁴UKGM Department of Pediatric Cardiology, Giessen, Germany, ⁵UKGM Hemostasis Center, Giessen, Germany
- PO1-18 **Is increased plasma levels of the amino acid triplet – cysteinylglycylcysteine-homocysteine-cysteine, may overtake the occurrence of thrombosis in cancer patients undergoing chemotherapy**
M. Kędzierska¹, U. Czernek¹, R. Głowacki², K. Borowczyk², E. Forma³, M. Bry³, K. Wójcik-Krowiranda⁴, A. Bienkiewicz⁴, J. Piekarski⁵, Piotr Potemski¹
¹Medical University of Lodz, Department of Chemotherapy, ²University of Lodz, Department of Environmental Chemistry, Lodz, Poland, ³University of Lodz, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, Lodz, Poland, ⁴Medical University of Lodz, Clinical Division of Gynecological Oncology, Lodz, Poland, ⁵Medical University of Lodz, Department of Surgical Oncology, Lodz, Poland
- PO1-19 **Prospective, Non-Interventional Study with Rivaroxaban or Standard of Care Anticoagulation for Initial Therapy and Secondary Prevention of Deep Vein Thrombosis – Subgroup Analysis of Patients in Germany (XALIA-DE)**
S. Haas¹, R. Kreutz², J. Beyer-Westendorf³, M. Gebel⁴, J. Herold³, J. Schneider⁵, P. Weyrauch⁵, R. Bauersachs⁴ for the XALIA-Study Group in Germany
¹TU Muenchen, Munich, Germany, ²Institut für klinische Pharmakologie und Toxikologie, Charite Berlin, Berlin, Germany, ³Universitätsklinik für Kardiologie, Angiologie und Pneumologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany, ⁴Klinik für Gefäßmedizin, Gefäßchirurgie und Angiologie, Klinikum Darmstadt, Darmstadt, Germany, ⁵Bayer-intern, Leverkusen, Germany, ⁶Universitätsklinikum Carl-Gustav-Carus, Universitäts-Gefäßzentrum, Dresden, Germany
- PO1-20 **Prothrombin G20210A Mutation in Sudanese Women with Recurrent Miscarriage**
M. Osman
 University of Khartoum, Hematology department, Faculty of Medical Laboratory Sciences, Khartoum, Sudan